Thus, although the classical IC blockade of the PD-1/PD-L1 signaling in AML is not as efficacious as in solid tumors, many other IC molecules have been identified on AML blasts and LSCs with the potential to become therapeutic targets in the future. Here, PDCD1 is linked to acute myeloid leukemia.